Real-time · AI · Cross-signal

Discover the power of real-time signals plus AI

Every contract, funding round, exec hire, and M&A move on Pillar Biosciences — with verified, ICP-scored contact reveals (email + mobile) on demand.

Trusted by founders, sales teams, recruiters, and investors at firms like BlackRock, Oracle, Kleiner Perkins, and HubSpot.

See plans Book a 15-min walkthrough

▶

Watch the 2-minute tour · with sound

Pillar Biosciences Partners with AstraZeneca to Accelerate Liquid Biopsy Testing

Sep 10, 2024•over 1 year ago

Contract Type

partnership

NatickBiotechnology

Description

Pillar Biosciences, Inc. has entered into a strategic partnership with AstraZeneca to expand laboratory access to molecular testing, using rapid, Next Generation Sequencing (NGS)-based liquid biopsy tumor profiling panels for detection of genetic cancer variants in European markets and the UK.

Company Information

Company

Pillar Biosciences

Location

Natick, Massachusetts, United States

About

Pillar Biosciences is the leader in Decision Medicine™, which is the utilization of highly accurate and sensitive next-generation sequencing (NGS) testing technology to generate data that optimizes selection of precision therapies for cancer patients, from tumor profiling to therapy selection, and recurrence monitoring. Pillar's NGS testing solutions are powered by its proprietary SLIMamp® and PiVAT® technologies, helping to localize the testing process, reduce diagnostic costs and improve access and efficiency of complex NGS testing for clinicians, prescribers, and patients globally. The company has more than 20 NGS testing kits available in IVD or RUO formats, with multiple panels in various stages of development. Pillar Biosciences has operations in Natick, MA.

Predictive Intelligence

Strategic

ML-powered predictions for Pillar Biosciences's next move

Learn about Strategic plan

Related People

Suggested for you

Agreement Insights

Based on industry data

Strategic partnership established

Partnership agreements typically involve technology integration and joint go-to-market strategies

Contract momentum indicator

Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months